monalizumab

Sponsor Astrazeneca PLC · listed as AZN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

monalizumab is a clinical-stage drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Sep 30, 2026 (day precision, medium confidence), tied to trial NCT05221840. The asset is in Phase 3 and currently active not recruiting, studied in Non-Small Cell Lung Cancer. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2026-09-30

As disclosedSep 30, 2026

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT05221840

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorAstraZeneca

Listed asAZN

Condition(s)Non-Small Cell Lung Cancer

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More AZN catalysts